3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Sell
40
VNDA Quote, Financials, Valuation and Earnings
Last price:
$4.99
Seasonality move
:
92.46%
Day range:
$4.84 - $5.05
52-week range:
$3.71 - $6.75
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.44x
P/B ratio:
0.53x
Volume:
358.6K
Avg. volume:
700.5K
1-year change:
28.13%
Market cap:
$286.9M
Revenue:
$198.8M
EPS (TTM):
-$0.32
Analysts' Opinion
-
Consensus RatingVanda Pharmaceuticals has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.67, Vanda Pharmaceuticals has an estimated upside of 157.45% from its current price of $4.92.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $5.00 representing 100% downside risk from its current price of $4.92.
Fair Value
-
According to the consensus of 2 analysts, Vanda Pharmaceuticals has 157.45% upside to fair value with a price target of $12.67 per share.
VNDA vs. S&P 500
-
Over the past 5 trading days, Vanda Pharmaceuticals has overperformed the S&P 500 by 4.72% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Vanda Pharmaceuticals does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Vanda Pharmaceuticals has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Vanda Pharmaceuticals reported revenues of $53.2M.
Earnings Growth
-
Vanda Pharmaceuticals earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Vanda Pharmaceuticals reported earnings per share of -$0.08.
Enterprise value:
-87.7M
EV / Invested capital:
-0.16x
Price / LTM sales:
1.44x
EV / EBIT:
--
EV / Revenue:
-0.44x
PEG ratio (5yr expected):
--
EV / Free cash flow:
5.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$187.5M
Return On Assets:
-2.9%
Net Income Margin (TTM):
-9.51%
Return On Equity:
-3.49%
Return On Invested Capital:
-3.49%
Operating Margin:
-19.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $254.4M | $192.6M | $198.8M | $45.3M | $53.2M | |
| Gross Profit | $230.1M | $177.8M | $187.5M | $41.8M | $50.6M | |
| Operating Income | $6.3M | -$14M | -$40.7M | -$7.1M | -$10.3M | |
| EBITDA | $9.1M | -$10.9M | -$32.5M | -$5.9M | -$8.3M | |
| Diluted EPS | $0.12 | $0.05 | -$0.32 | -$0.04 | -$0.08 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $409.1M | $478.3M | $519.3M | $432.9M | $438.9M | |
| Total Assets | $533.5M | $593.8M | $634.2M | $648.4M | $656.2M | |
| Current Liabilities | $65.9M | $74.4M | $91.4M | $87.7M | $100M | |
| Total Liabilities | $80.2M | $88.9M | $107M | $103.5M | $117.7M | |
| Total Equity | $453.3M | $504.9M | $527.2M | $544.9M | $538.5M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $32M | $12.8M | -$15.8M | -$3.7M | -$1.8M | |
| Cash From Investing | $49.9M | -$12.1M | -$17.4M | -$43.8M | $4M | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | $31.3M | $12.4M | -$16.2M | -$4M | -$2M | |
VNDA
Sector
Market Cap
$286.9M
$38.4M
Price % of 52-Week High
72.89%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
28.13%
-39.05%
Beta (5-Year)
0.689
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$4.91
200-day SMA
Sell
Level
$5.06
Bollinger Bands (100)
Buy
Level
4.51 - 4.99
Chaikin Money Flow
Sell
Level
-143.4M
20-day SMA
Buy
Level
$4.72
Relative Strength Index (RSI14)
Buy
Level
56.51
ADX Line
Buy
Level
15.33
Williams %R
Neutral
Level
-30.3371
50-day SMA
Buy
Level
$4.64
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
52
On Balance Volume
Neutral
Level
63.6M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.7707)
Buy
CA Score
(Annual)
Level (0.8902)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-2.1095)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
Stock Forecast FAQ
In the current month, VNDA has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The VNDA average analyst price target in the past 3 months is $12.67.
-
Where Will Vanda Pharmaceuticals Stock Be In 1 Year?
According to analysts, the consensus estimate is that Vanda Pharmaceuticals share price will rise to $12.67 per share over the next 12 months.
-
What Do Analysts Say About Vanda Pharmaceuticals?
Analysts are divided on their view about Vanda Pharmaceuticals share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Vanda Pharmaceuticals is a Sell and believe this share price will drop from its current level to $5.00.
-
What Is Vanda Pharmaceuticals's Price Target?
The price target for Vanda Pharmaceuticals over the next 1-year time period is forecast to be $12.67 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is VNDA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Vanda Pharmaceuticals is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of VNDA?
You can purchase shares of Vanda Pharmaceuticals via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Vanda Pharmaceuticals shares.
-
What Is The Vanda Pharmaceuticals Share Price Today?
Vanda Pharmaceuticals was last trading at $4.99 per share. This represents the most recent stock quote for Vanda Pharmaceuticals. Yesterday, Vanda Pharmaceuticals closed at $4.92 per share.
-
How To Buy Vanda Pharmaceuticals Stock Online?
In order to purchase Vanda Pharmaceuticals stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Alerts
Sell
5
CABO alert for Mar 14
Cable One [CABO] is down 3.97% over the past day.
Sell
38
ADBE alert for Mar 14
Adobe [ADBE] is up 4.43% over the past day.
Sell
29
CAR alert for Mar 14
Avis Budget Group [CAR] is up 11.68% over the past day.
